glp 1 and synthroid Suppressed thyroid stimulating hormone levels after initiation of a subcutaneous glucagon-like peptide-1 receptor agonist in a post-thyroidectomy patient managed with levothyroxine case report The Truth About GLP-1s, Thyroid

Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis

doi: 10.3389/fbioe.2025.1729166 Received 21 October 2025 Revised 01 December 2025 Accepted 17 December 2025 Published 15 January 2026 Volume 13 - 2025 Edited by Ling Wang, Dalian Medical University, China Reviewed by Nicola Alessio, University of Campania Luigi Vanvitelli, Italy Yesuf Adem Siraj, Bahir Dar University, Ethiopia Updates Copyright 2026 Hu, Li, Hu, Shan, Tang, Jiang, Yi, Chen, Jin, Wang and Wang

Which patients may prefer pills

Our electronic prior authorization (ePA) solution provides a safety net to ensure the right information needed for a determination gets to patients' health plans as fast as possible

Who is eligible to take GLP-1 medications